Recently, the China Chamber of Commerce for Import and Export of Medicines and Health Products (hereinafter referred to as the “Medical Insurance Chamber of Commerceâ€) released the export data of China's pharmaceutical exports in 2017. Statistics show that in 2017, China's exports of pharmaceutical and health care products increased by 9.44% year-on-year to reach 60.799 billion US dollars, the largest increase in the past five years, successfully reversed the decline in the previous year. The export volume of Chinese and Western medicines increased double. In 2017, China's exports of traditional Chinese medicine products amounted to US$3.640 billion, up 2.07% year-on-year; the export performance of Western medicine products rebounded significantly, with exports amounting to US$35.456 billion, up 12.62% year-on-year.
Meng Dongping, vice president of the Medical Insurance Chamber of Commerce, said: "Overall, the demand for international pharmaceutical market has increased in 2017; China's supply-side structural reforms have begun to bear fruit, new development momentum is taking shape, and Chinese pharmaceuticals are forming unique differentiation in the international market. With the competitive advantage, the export volume of pharmaceutical products has increased and the price has increased steadily, and the export volume has increased steadily."
It is understood that after years of accumulation, China's pharmaceutical companies have climbed step by step from raw materials, low-end preparations, high-end preparations, me too, me better, and me best. Although the level of repetition is still relatively high, the overall level of innovation is not so high. But the rise is inevitable.
Among them, innovative pharmaceutical companies have become the main force driving the export of Chinese preparations. Local pharmaceutical companies such as Hengrui Medicine and Qilu Pharmaceutical have successfully established themselves in the European and American markets and have begun to make a difference. Meng Dongping said, "Local pharmaceutical companies can establish themselves in the international mainstream markets such as Europe and the United States, which not only benefits the export of Chinese pharmaceutical products, but also allows people to see the development momentum of Chinese pharmaceuticals."
Taking Hengrui Medicine as an example, its R&D strength is strong, and its product line is rich in research. In the next three years, it will enter the “Innovative Medicine + Preparation Export†harvest period, and its overseas market layout will be gradually improved and expanded.
R&D has a future, and more and more companies are willing to invest in R&D, and the proportion of revenue in the company is also increasing. The author has learned that the two main lines of China's pharmaceutical industry improvement have become increasingly clear. One is to encourage real innovation in the policy, and to enable innovative enterprises to come out and kill them to meet the unmet clinical needs of the people; Through the consistency evaluation, the level of Chinese generic pharmaceutical companies has been improved, and the public has been guaranteed to use safer and more reliable generic drugs.
Nowadays, China's innovative drugs are rising. The cases of foreign biopharmaceutical companies introducing Chinese pharmaceutical companies to independently research and develop innovative drugs' overseas interests are increasingly common, and the scale of transactions is getting higher and higher. In 2017, the transformation of China's pharmaceutical R&D results began to enter the harvest period, and the company newly obtained 34 USCIC applications (ANDA) number (eight of which were temporarily approved), which was 1.7 times of the number approved last year. More and more companies are going abroad to enter the US generic drug market.
From the data of China's pharmaceutical foreign trade export in 2017, although China's pharmaceutical industry is forming a unique differentiated competitive advantage in the international market, it has to admit that there are still some differences between China's pharmaceutical market and the international market. It is understood that China's domestic pharmaceutical research and development innovation level is still in the third echelon. Among the annual R&D contributions, the products developed by Chinese companies are in the third echelon for global innovation contributions.
At present, the degree of internationalization of Chinese medicine is relatively low, and the total amount of exports is relatively small. According to statistics, China's largest pharmaceutical company now has an average annual export volume of less than 100 million. 54% of exports are to Asia and Africa, while exports from Europe and the United States account for only 29%. Therefore, to become an advanced manufacturing country, the pharmaceutical industry still has a long way to go. Despite this, I believe that with the continuous introduction of favorable national policies, China's pharmaceutical industry will be vigorously developed. With the implementation of the “13th Five-Year Plan†API, China's pharmaceutical industry will develop in a more orderly, higher-tech content, environmental protection, resource conservation, value-added, and downstream extension, which is more conducive to the export structure. Continuously optimize the upgrade. It is expected that the fundamentals of the steady development of pharmaceutical foreign trade in 2018 will continue to be maintained.
Collapsible Foot Spa,Foot Spa Bath Massager,Foot Bath Spa Massager,Foot Soak Tub
Huaian Mimir Electric Appliance Co., LTD , https://www.mmfootbath.com